How it Works

Through in-licensing, we partner with leading neurotech innovators and transform revolutionary therapeutics into differentiated treatments that improve patients’ lives. Our established capabilities and top-notch resources would be the critical catalyst for a product to achieve its full potential in China market.

Meanwhile, by providing project funding to compelling innovations, we empower a product to evolve locally and create scalable value for stakeholders.

For top-tier innovators with a shared mission, we together form a Joint Venture to gain a tactical and strategic edge in the China market and deliver transformative outcomes for patients.

By integrating the strengths, such a collaborative approach would further synergize our efforts to turn promising inventions into clinical-ready assets and fuel innovations in areas with unmet medical needs.

Situated in Asia’s most prominent biotech fundraising hub – Hong Kong, we work with the best-in-kind investors to raise capital funding for the phased advancement of acquired cutting-edge technologies. We seek therapies with the highest clinical promise and pair them with the proper financing to promote new product development.

Extending beyond Hong Kong, we integrate with the Greater Bay Area and benefit from mainland China’s leading CRO and CDMO networks. Local development and manufacturing will involve much lower COGS and provide the benefits of better tax treatment and support in regulatory approval, allowing us to flexibly scale across programs, return more value to our stakeholders and deliver profound treatment improvements to patients.

Government policy and regulations can often significantly impact the timeline and cost of market entry. We manage the regulatory complexities and closely work with regulatory specialists to identify the optimal NMPA submission pathway and ensure our products are commercialized to the highest standards.

In China, provincial-level organs set up local reimbursement and hospital listing requirements, giving rise to an isolated, distinct reimbursement system in each province. We partner with medical listing and insurance experts to prepare, submit, and manage local reimbursement applications and ensure a product enters medical insurance quickly.

China is a collection of socially and economically disparate sub-markets defined by vastly differing demographics, economic and cultural characteristics. For example, there are huge variations between different provinces regarding population, average income, consumer spending habits, per capita GDP, etc.

Furthermore, individual province has its own reimbursement and hospital system, making it even more challenging for foreign companies to enter the space. Therefore, it is crucial to partner with a local expert like us to identify the target markets and tailor the product strategy to the unique market needs.

With over 25 years of experience in healthcare, MaxNova has established marketing and sales channels covering all of China, including over 10,000 public hospitals and essential access to key opinion leaders. Through collaborating with marketing teams with extensive product launch expertise, we will tailor a sales plan for each product and leverage our diverse channels to reach maximum market coverage.

In addition, our value proposition of developing meaningful innovations to improve patient life quality will further help grow the brand and engage with patients, clinicians, and hospitals.